MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone818-661-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.86 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) announced its quarterly earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts' consensus estimates of $0.22 by $0.28. During the same quarter in the previous year, the business earned ($0.28) EPS. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
4 equities research analysts have issued 1 year price objectives for MannKind's stock. Their predictions range from $3.00 to $4.00. On average, they expect MannKind's share price to reach $3.3333 in the next twelve months. This suggests a possible upside of 56.5% from the stock's current price. View Analyst Price Targets for MannKind.
What is the consensus analysts' recommendation for MannKind?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MannKind.
What are Wall Street analysts saying about MannKind stock?
Here are some recent quotes from research analysts about MannKind stock:
- 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (7/11/2018)
- 2. HC Wainwright analysts commented, "Exchange NASDAQ Value (M) $324.5 Market Cap (M) $238 Shares Outstanding (M) 133.1 3 Interest (M) 32.53 Cash (M) $53.5 Total Debt (M) $140.0 Year – (0.15) FY (1.13) (0.83) (0.65) FY P/E NM NM NM Year – 14.7 FY 11.7 20.8 45.4 8 6 4 2 0 0 Vol. (mil) the science to drive Afrezza awareness and adoption." (5/10/2018)
Has MannKind been receiving favorable news coverage?
News coverage about MNKD stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MannKind earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting MannKind?
MannKind saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 35,483,107 shares, an increase of 2.5% from the February 15th total of 36,396,016 shares. Based on an average daily volume of 4,430,235 shares, the short-interest ratio is currently 8.0 days. Approximately 20.5% of the company's shares are short sold. View MannKind's Current Options Chain.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Puma Biotechnology (PBYI), Wave Life Sciences (WVE), Prestige Consumer Healthcare (PBH), Innoviva (INVA), Clovis Oncology (CLVS), Theravance Biopharma (TBPH), Gossamer Bio (GOSS), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Cambrex (CBM), TherapeuticsMD (TXMD), Phibro Animal Health (PAHC), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR) and Spectrum Pharmaceuticals (SPPI).
What other stocks do shareholders of MannKind own?
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 42)
- Mr. Steven B. Binder, Chief Financial Officer (Age 56)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 55)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 58)
- Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 52)
Who are MannKind's major shareholders?
MannKind's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.41%), CVI Holdings LLC (6.71%), Raging Capital Management LLC (2.16%), Highbridge Capital Management LLC (1.57%), Geode Capital Management LLC (1.04%) and Geode Capital Management LLC (1.04%). Company insiders that own MannKind stock include Kent Kresa, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.
Which major investors are selling MannKind stock?
MNKD stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Northern Trust Corp, Two Sigma Advisers LP and Principal Financial Group Inc.. View Insider Buying and Selling for MannKind.
Which major investors are buying MannKind stock?
MNKD stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Raging Capital Management LLC, Highbridge Capital Management LLC, Geode Capital Management LLC, Geode Capital Management LLC, BlackRock Inc., Raymond James & Associates and Rhumbline Advisers. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Michael Castagna, Rosabel Realica Alinaya, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $2.13.
How big of a company is MannKind?
MannKind has a market capitalization of $399.03 million and generates $27.86 million in revenue each year. The biopharmaceutical company earns $-86,970,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.
What is MannKind's official website?
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (NASDAQ MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
